Overall genomic pattern is a predictor of outcome in XXXX .

@entity1 @entity5 @entity1347 @entity521 @entity4180 @entity204
PURPOSE: For a comprehensive overview of the genetic alterations of @entity521 , their association and clinical significance, we conducted a whole-genome DNA copy number analysis. @entity1 AND METHODS: A series of 493 @entity521 ( @entity521 ) samples was investigated by array-based comparative genomic hybridization in two consecutive steps (224, then 269 @entity1 ). RESULTS: Genomic analysis identified several types of profiles. Tumors presenting exclusively whole-chromosome copy number variations were associated with excellent survival. No @entity204 was observed in this group. In contrast, @entity5 with any @entity1347 characterized @entity1 with a high risk of relapse. @entity1 with both numerical and @entity1347 clearly shared the higher risk of relapse of @entity1347 @entity1 . In a multivariate analysis, taking into account the genomic profile, but also previously described individual genetic and clinical markers with prognostic significance, the presence of segmental alterations with (HR, 7.3; 95% CI, 3.7 to 14.5; P < .001) or without @entity4180 amplification (HR, 4.5; 95% CI, 2.4 to 8.4; P < .001) was the strongest predictor of relapse; the other significant variables were age older than 18 months (HR, 1.8; 95% CI, 1.2 to 2.8; P = .004) and stage 4 (HR, 1.8; 95% CI, 1.2 to 2.7; P = .005). Finally, within @entity5 showing segmental alterations, stage 4, age, @entity4180 amplification, 1p and 11q deletions, and 1q gain were independent predictors of decreased overall survival. CONCLUSION: The analysis of the overall genomic pattern, which probably unravels particular genomic instability mechanisms rather than the analysis of individual markers, is essential to predict relapse in @entity521 @entity1 . It adds critical prognostic information to conventional markers and should be included in future treatment stratification.
